Staphylococcal coagulase antigens and methods of their use
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium . The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve coagulase Domains 1-2 and variants thereof.
1. An immunogenic composition comprising a first staphylococcal coagulase Domains 1-2 from a first staphylococcal strain and a second staphylococcal coagulase Domains 1-2 from a second staphylococcal strain, wherein the first and second staphylococcal strains are different from each other, wherein each Domains 1-2 is 80% identical in sequence to a Domains 1-2 sequence in SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 41, and wherein at least one Domains 1-2 is comprised in a less than full-length coagulase protein that is truncated on the C terminus.
2. The composition of claim 1 , wherein the less than full-length coagulase protein lacks all or part of a L or R Domain segment.
3. The composition of claim 1 , wherein the less than full-length coagulase protein lacks all or part of a L or F Domain segment.
4. The composition of claim 1 , wherein one of the Domains 1-2 is from a S. aureus Newman, 85/2082, MW2, MSSA476, N315, Mu50, MRSA252, CowanI, WIS or USA300 strain.
5. The composition of claim 1 , wherein one of the Domains 1-2 is a Coa Domains 1-2 at least 80% identical in sequence to SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, or SEQ ID NO: 37.
6. The composition of claim 1 , wherein one of the Domains 1-2 is a vWbp Domains 1-2 at least 80% identical in sequence to SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 41.
7. A method for treating a staphylococcal infection in a subject comprising administering to the subject an effective amount of a composition of claim 1 .
8. The composition of claim 1 , wherein each Domains 1-2 is at least 85%, 90% or 95% identical to an amino acid sequence of SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, SEQ ID NO: 40, or SEQ ID NO: 41.
9. The composition of claim 1 , wherein one of the Domains 1-2 is a vWbp Domains 1-2 from a S. aureus N315 or USA300.
10. The composition of claim 1 , wherein one of the Domains 1-2 is a Coa Domains 1-2 and comprises a L or R Domain from a staphylococcal Coa protein.
11. The composition of claim 1 , wherein one of the Domains 1-2 is a vWbp Domains 1-2 and comprises an L or Fgb domain from a staphylococcal vWbp protein.
12. The composition of claim 1 , comprising at least three, four or five different staphylococcal coagulase Domains 1-2.
13. The composition of claim 12 , comprising at least four different staphylococcal coagulase Domains 1-2 wherein the different Domains 1-2 are staphylococcal Coa Domains 1-2 from strains MRSA252, MW2, N315 and USA300.
14. The composition of claim 1 , wherein the first and second staphylococcal coagulase Domains 1-2 are comprised in a fusion protein.
15. The composition of claim 1 , further comprising one or more additional staphylococcal antigen(s).
16. The composition of claim 15 , wherein the additional staphylococcal antigen(s) is Emp, EsxA, EsxB, EsaC, Eap, Ebh, EsaB, Coa, vWbp, vWh, Hla, SdrC, SdrD, SdrE, IsdA, IsdB, IsdC, ClfA, ClfB, SasF and/or a nontoxigenic SpA.
17. The composition of claim 1 , further comprising an adjuvant.
18. The composition of claim 1 , wherein the first and second staphylococcal coagulase Domains 1-2 are recombinant polypeptide(s).
19. The composition of claim 1 , further comprising at least four different staphylococcal coagulase Domains 1-2 wherein the composition comprises at least staphylococcal Coa Domains 1-2 from strains MRSA252, MW2, N315 and USA300 and vWbp Domains 1-2 from a S. aureus N315 and USA300.
20. The composition of claim 19 , wherein the composition comprises a R Domain from a staphylococcal Coa protein or a CT domain of vWbp.
21. A method for treating and/or preventing a staphylococcal infection in a subject comprising administering to the subject an effective amount of a composition of claim 19 .